MARKET

SHPH

SHPH

SHUTTLE PHARMACTCLS HLDGS INC
NASDAQ
0.2325
-0.0375
-13.89%
After Hours: 0.2429 +0.0104 +4.47% 19:59 05/09 EDT
OPEN
0.4430
PREV CLOSE
0.2700
HIGH
0.4500
LOW
0.2104
VOLUME
185.87M
TURNOVER
--
52 WEEK HIGH
4.710
52 WEEK LOW
0.2104
MARKET CAP
1.45M
P/E (TTM)
-0.0730
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 16h ago
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket
Benzinga · 18h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 1d ago
Shuttle Pharma Announces FDA Orphan-Drug Nears Patient Enrollment Milestone For Phase 2 Clinical Trial
Benzinga · 1d ago
Shuttle Pharmaceuticals Has Been Granted A European Patent Titled "DUAL FUNCTION MOLECULES FOR HISTONE DEACETYLASE INHIBITION AND ATAXIA TELANGIECTASIA MUTATED ACTIVATION (FOR TREATMENT OF CANCERS, NEUROLOGICAL DISORDERS, & IMMUNOLOGICAL DISORDERS)"
Benzinga · 2d ago
Weekly Report: what happened at SHPH last week (0428-0502)?
Weekly Report · 4d ago
Weekly Report: what happened at SHPH last week (0421-0425)?
Weekly Report · 04/28 11:38
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 04/25 21:06
More
About SHPH
More
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
Recently
Symbol
Price
%Change

Webull offers Shuttle Pharmaceuticals Holdings Inc stock information, including NASDAQ: SHPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SHPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SHPH stock methods without spending real money on the virtual paper trading platform.